| Expression pattern: |
UP |
| Associated gene: |
ANXA2 |
| Associated microRNA: |
MiR-23a-5p, miR503-3p |
| Biological function: |
Associated with shorter overall survival and adverse cytogenetic pattern; predicts lower CR achievement in AML patients. |
| Molecular mechanism: |
miRNA sponge (ceRNA-like): sponges MiR-23a-5p and miR503-3p; reported to augment transcription of parental gene ANXA2 and may reduce chemosensitivity. |
| Biological pathway or process: |
ceRNA regulation (other); chemoresistance (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; ROC Analysis; Survival Analysis |
| Clinical significance: |
Diagnostic biomarker for AML (AUC 0.824); high expression correlates with shorter overall survival and adverse cytogenetic pattern; independent predictor of CR achievement. |
| Description: |
circANXA2 is up-regulated in AML whole blood and has diagnostic value (AUC 0.824). High circANXA2 associates with adverse clinical features and shorter overall survival, and it is an independent predictor of complete remission achievement. Mechanistically, it is discussed as a miRNA sponge (MiR-23a-5p/miR503-3p) and linked to ANXA2 transcription and chemotherapy sensitivity. |
| Confidence score: |
0.4758 |